TOLNAFTATE- tolnaftate cream Major Pharmaceuticals

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Drug Facts

Active ingredient

Tolnaftate USP 1%

Purpose

Antifungal

Uses

- for effective treatment of most athlete's foot (tinea pedis), jock itch (tinea cruris) and ringworm (tinea corporis)
- for effective relief of itchy, scaly skin between the toes
- clears up most athlete's foot infection and with daily use helps keep it from coming back

Warnings

For external use only

Do not use

• on children under 2 years of age unless directed by a doctor

When using this product avoid contact with eyes

Stop use and ask a doctor if

- irritation occurs or if there is no improvement within 4 weeks (for athlete's foot and ringworm)
- irritation occurs or if there is no improvement within 2 weeks (for jock itch)

Keep this and all drugs out of the reach of children.

In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

Directions

- clean the affected area and dry thoroughly
- apply a thin layer of the product over the affected area twice daily (morning and night) or as directed by a doctor
- supervise children in the use of this product

For athlete's foot

- use daily for 4 weeks. If condition persists longer, consult a doctor
- pay special attention to the spaces between the toes
- wear well fitting ventilated shoes
- change shoes and socks at least once daily

For ringworm, use daily for 4 weeks. If condition persists longer, consult a doctor. For jock itch, use daily for 2 weeks. If condition persists longer, consult a doctor. This product is not effective on the scalp or nails.

Other information

- Store at controlled room temperature 15°-30°C (59°-86°F)
- Lot No. and Exp date: see crimp on tube or see box

Inactive ingredients

Ceteth-20, Cetostearyl Alcohol, Chlorocresol, Mineral Oil, Propylene Glycol, Purified Water, Sodium Phosphate Monobasic, White Petrolatum

Questions?

Adverse Drug Event call (800)616-2471 Dist. By MAJOR PHARMACEUTICALS, 31778 Enterprise Drive, Livonia, MI 48150 USA Re-Oder No. 100497 M-88 Rev. 9/09 Manufactured in USA

Principal Display Panel – 0.5 oz Tube

 $\textbf{MAJOR}^{\texttt{®}}$ *Compare to Active Ingredient of Tinactin ®

NDC 0904-0722-36

Antifungal

Cream (Tolnaftate 1%) N309040722362

CURES ATHLETE'S FOOT, *This product is not manufactured or

JOCK ITCH AND RINGWORM distributed by Schering-Plough Healthcare

Relives Burning and Itching Products, Inc. owner of the registered

• Odorless • Greaseless • Non-Staining trademark, Tinactin®

Net Wt. 0.5 OZ (14.18 g)

Product Informa									
Product Type		HUMAN OTC DRUG	Ite m C	Item Code (Source)		NDC:0904-0722			
Route of Administra	ition	TOPICAL							
Active Ingredien		ety redient Name							
		of Strength	Strength						
TOLNAFTATE (UNII: 06KB629TKV) (TOLNAFTATE - UNII:06KB629TKV) TOLNAFTATE						10 mg in 1 g			
Inactive Ingredie	ents								
Ingredient Name									
Ingredient Name Strength WATER (UNII: 059QF0K00R)									
CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)									
CETETH-20 (UNII: 1835H2IHHX)									
CHLOROCRESOL (U	NII: 36 W530710	9)							
MINERAL OIL (UNII:	T5L8T28FGP)								
PETROLATUM (UNII: 4T6H12BN9U)									
SO DIUM PHO SPHAT	E, MONOBASIC	, Anhydrous (Unii: Kh	17104HPUU)						
PROPYLENE GLYCO	L (UNII: 6DC9Q	167V3)							
Packaging									
# Item Code		kage Description	Marketin	ıg Start Date	Marketing End Date				
1 NDC:0904-0722-36	1 in 1 CA								
1	14.18 g li	n 1 TUBE							
Marketing Inf	ormation								
0		Application Number or Monograph Citation		Marketing Start	Date Marke	Marketing End Date			
Marketing Categor	y Application	on Number of Monogra	F	0		8			

Labeler - Major Pharmaceuticals (191427277)

Registrant - Faria Limited dba Sheffield Pharmaceuticals (151177797)

Establishment

Name	Address	ID/FEI	Business Operations
Faria LLC dba Sheffield Pharmaceuticals		151177797	MANUFACTURE(0904-0722)

Revised: 7/2013

Major Pharmaceuticals